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Abstract
Background and objectives: Treatment options for oesophageal cancer have changed considerably over the last
decades with the introduction of multimodal treatment concepts dominating the progress in the field. However, it
remains unclear in how far the documented scientific progress influenced and changed the daily routine practice.
Since most patients with oesophageal cancer generally suffer from reduced overall health conditions it is uncertain
how high the proportion of aggressive treatments is and whether outcomes are improved substantially. In order to
gain insight into this we performed a retrospective analysis of patients treated at a larger tertiary referral centre
over time course of 25 years.
Patients and methods: Data of all patients diagnosed with squamous cell carcinoma (SCC) and adenocarcinoma
(AC) of the oesophagus, treated between 1983 and 2007 in the department of radiation oncology of the LMU,
were obtained. The primary endpoint of the data collection was overall survival (calculated from the date of
diagnosis until death or last follow up). Changes in basic clinical characteristics, treatment approach and the effect
on survival were analysed after dividing the cohort into five subsequent time periods (I-V) with 5 years each. In a
second analysis any pattern of change regarding the use of radio(chemo)therapy (R(C)T) with and without surgery
was determined.
Results: In total, 503 patients with SCC (78.5%) and AC (18.9%) of the oesophagus were identified. The average
age was 60 years (range 35-91 years). 56.5% of the patients were diagnose with advanced UICC stages III-IV. R(C)T
was applied to 353 (70.2%) patients; R(C)T+ surgery was performed in 134 (26.6%) patients, 63.8% of all received
chemotherapy (platinum-based 5.8%, 5-fluorouracil (5-FU)12.1%, 42.3% 5-FU and mitomycin C (MMC)). The median
follow-up period was 4.3 years. The median overall survival was 21.4 months. Over the time, patients were older,
the formal tumour stage was more advanced, the incidence of AC was higher and the intensified treatment had a
higher prevalence. However there was only a trend for an improved OS over the years with no difference between
RCT with or without surgery (p = 0.09). The use of radiation doses over 54 Gy and the addition of chemotherapy
(p = 0.002) were associated with improved OS.
Conclusion: Although more complex treatment protocols were introduced into clinical routine, only a minor
progress in OS rates was detectable. Main predictors of outcome in this cohort was the addition of chemotherapy.
The addition of surgery to radio-chemotherapy may only be of value for very limited patient groups.
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Oesophageal cancer is generally associated with poor
outcomes. However, over the last decades the treatment
algorithms have changed considerably shifting from sin-
gle mode treatments to complex multimodal approaches
[1,2].
Surgery is considered to be the mainstay of treatment
especially in earlier stages, however a clear superiority
over definitive radio-chemotherapy has not been proven
so far [3]. In contrast, for locally advanced stages 5-
fluorouracil (5-FU)/cisplatin based radio-chemotherapy
(RCT) regimens are the standard of care either in neo-
adjuvant or definitive concepts [4-11].
Although several trials and subsequent meta-analysis
revealed a benefit for more aggressive approaches - at least
in some sub-groups - the benefit in daily routine settings
remains poorly defined. Since patients with oesophageal
cancer frequently suffer from various comorbidities
increasing the aggressiveness of any treatment may only
be of value for a very limited subgroup of those patients
[6,7,11,12].
The introduction of radio-chemotherapy protocols,
regardless of the use of platinum, offer a clear advantage
when compared to radiotherapy alone [7,13,14].
The analysis of triple modality approaches leads to a
more complex picture: The French FFCD 9102 trial
compared radio-chemotherapy plus surgery to radio-
chemotherapy alone. Local control and overall survival
were almost identical at 2-years with a perioperative
mortality of approximately 10% [4]. The authors con-
clude that there are no clear-cut benefits from the addi-
tion of surgery. Data from a similar German trial
support these interpretations [9].
Nevertheless, the best outcomes were obtained in those
patients with good response after neo-adjuvant RCT and
complete resection during subsequent surgery. However,
the benefits of improved local control are - at least par-
tially - outweighed by increased surgical morbidity.
A meta-analysis resulted in improved survival rates
when the outcomes of RCT followed by surgery were
compared with surgery alone [12,15]. However this ana-
lysis did not really address the question in how far sur-
gery is needed after good responses to RCT.
The value of most clinical trials on oesophageal cancer
is limited to some degree because the clinical status of
many of the patients in the ‘real-live’ setting prohibits
the use of aggressive multi-modal protocols and thus
the results of the respective trial may not be transferable
to most patients.
In order to re-assess the value of different treatment
approaches in oesophageal cancer in real life settings we
analysed patient characteristics, stages distributions,
treatment approaches and outcomes in a cohort of
patients treated in one tertiary referral-centre over the
last 25 years.
Materials and methods
Patients
In a retrospective approach, the following data were sys-
tematically retrieved from the original patient files:
tumour stage (TNM/UICC version 6), treatment and
outcome of all patients with either squamous cell carci-
noma (SCC) or adenocarcinoma (AC) of the thoracic
oesophagus, excluding AC from cardia and gastric invol-
vement (GEJII+III). All retrospectively collected patient
data were compared and crosschecked to data docu-
mented prospectively by the population-based Munich
Cancer Registry (MCR, documentation started in 1978)
for accuracy and completeness to prove the reliability
and validity of our data.
Patients were treated between 1983 and 2007 at the
department of radiation oncology at the hospital of the
Ludwig Maximilian University. For this analysis all
patients that presented with oesophageal carcinoma in
this department were included, regardless of the form of
therapy they received. Overall survival was defined as
the survival time from diagnosis to death. Calculations
for statistical significance were done only for non-meta-
static (M0) patients. A previous published study ana-
lysed a subgroup of this collective in order to determine
if a definitive RCT with 5 FU and mitomycin C is as
effective as the standard protocol with 5 FU/cisplatin
[13].
Statistics
Patient characteristics were compared by the Chi-square
test. Survival data were analysed according to Kaplan-
Meier (SPSS/WPSS
® 18.0/19.0). Statistical significance
was assessed by univariate and multivariate Cox propor-
tional hazards regression model (p < 0.05) and the log
rank test. Patients who were coded as “alive” were cen-
sored at the time of last follow-up.
In order to visualize potential time trends, the whole
cohort was arbitrarily divided into five treatment periods
(five years duration): period I = 1983-1987, II = 1988-
1992, III = 1993-1997, IV = 1998-2002, V = 2003-2007.
Results
Patients
A total of 503 patients with cancer of the oesophagus
were identified. The average number of patients treated
per year was 20 (range 6-36). Table 1 shows the patient
characteristics of the study population. The median age
at diagnosis was 61 years (range 35 to 91 years), 10%
were younger than 47 years, 10% older than 77 years at
diagnosis.
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ian age of 65 compared to SCC with a median age of 60
years at diagnosis. 20.8% SCC and 38.9% AC were older
than 70 years at diagnosis (p < .0001), they also present
a worse grading (p = 0.02) and unfavourable staging
with more metastatic disease (p = 0.04). Histology distri-
bution was independent of gender (Table 2).
At diagnosis 311 of all patients (62.5%) were classified
as ≥UICC stage IIB, 113 (22.5%) already presented with
metastatic disease, 60 (11,9%) were diagnosed with other
malignancies such as tumours of the oral cavity, SCLC,
bladder cancer etc.
The predominant tumour sites were the mid- and the
lower thoracic third with 147 (29.2%) and 201 (40%).
SCC was found in all subsections (26% cervical, 33%
mid-oesophagus, 35% distal). AC predominantly in the
distal third (65%) of the oesophagus (Table 1).
Treatment strategy
353 (70.2%) patients were considered to be inoperable
because of poor KPS, co-morbidities, locally non-resect-
able or metastatic disease. 172 (34.2%) received radio-
therapy only (RT), 322 (64%) radio-chemotherapy (RCT).
Treatment groups were divided in two major categories:
RT or RCT as definitive treatment (n = 353, 70.2%) and
RT/RCT combined with surgery (n = 134, 26.6%). In the
surgery group 51 patients (38%) received adjuvant and 83
(61.9%) neoadjuvant R(C)T. A two-agent chemotherapy
Table 1 Patient characteristics and treatment options, all
patients, 1983-2007
Variable Subgroup n = 503 %
Gender M 400 79.5
W 103 20.5
Age < 50 73 14.5
50-59 158 31.4
60-69 151 30
70+ 121 24.1
median y 61
range y 35-91
Histology AC 95 18.9
SCC 395 78.5
unknown 13 2.6
Grading G1+2 217 43.2
G3+4 262 52.1
unknown 14 2.8
T T1+2 114 22.7
T3 259 51.5
T4 90 17.9
unknown 39 7.8
N N0 203 40.4
N1 253 50.3
unknown 47 9.3
M M1 113 22.5
unknown 28 5.6
UICC I-IIB 190 37.8
III+IV 281 55.9
unknown 32 6.4
Localisation cervical 23 4.6
upper thoracic 114 22.7
mid thoracic 147 29.2
lower thoracic 201 40
unknown 18 3.6
Therapy prim. 353 70.2
RT/RCT 125/227 (35.4/64.3)
adjuvant 51 10.1
RT/RCT 20/28 (39.2/54.9)
neoadj. 83 16.5
RT/RCT 17/63 (20.5/75.9)
unknown 16 3.2
RT 172 34.2
RCT 322 64
unknown 9 1.8
Chemotherapy 322 100
5FU+MMC 213 66.1
5FU+Cisplatin 22 6.8
5FU 61 18.9
cisplatin 8 2.5
unknown 18 5.6
RT dose in Gy ≤50 151 30
> 50-≤54 72 14.3
≥54- < 60 85 16.9
Table 2 Distribution of adenocarcinoma (AC) and
squamous cell carcinoma (SCC)
SCC (n = 395) AC (n = 95) p-value
Male 317(80.3) 71(74.7) 0.23
Age
< 60 195(49.4) 32(33.7) 0.006
60-69 118(29.9) 26(27.4)
70- 82(20.8) 37(38.9) < 0.0001
G3+4 192(48.6) 61(64.2) 0.02
T1-2 94(25.5) 17(20.5) 0.33
T3 201(50.9) 51(53.7) n.s.
T4 73(18.5) 15(15.8) n.s.
N+ 198(50.1) 48(50.5) n.s.
M1 83(22.0) 28(32.2) 0.04
Table 1 Patient characteristics and treatment options, all
patients, 1983-2007 (Continued)
≥60 168 33.7
unknown 17 3.4
2D/3Dplanning 2D 289 57.5
3D 180 35.8
AL only 7 1.4
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5FU or cis-platinum in 30.7%. The radiation dose was
below 50 Gy in 151 (30%) patients, between 50 and 59
Gy in 157 (31.2%) and in 168 (33.7%) 60 Gy or more.
Radiotherapy was applied by a 3 D conformal CT-plan in
180 (35.8%) patients since 1998, a 2 D technique was
used before 1998 in 289 (57.5%) cases.
62 patients (12.3%) died during or shortly after treat-
ment i.e. intraoperative (3 patients), after surgery (23
patients (17,2%) from 134 who received surgery), before,
during or less than 4 weeks after R(C)T (53 patients (15%)
from 353). Considering M0 patients the rate declines to
9.8% for definitive R(C)T but remains the same for the
surgery group. In 43 (8.5%) patients treatment was
stopped prematurely. The proportion of patients older
than 65 who underwent surgery was half of number of
patients below 65 (p < .0001). 70% of the patients received
chemotherapy in the definitive RT group whereas only
30% in the surgery group (Table 1).
Time trends
Changes in patient characteristics, therapeutic strategies
The average age at diagnosis increased from 59 y to
65 y. The underlying histology shifted from SCC to AC
in our cohort with a significant rise in the prevalence of
AC from 16.1% to 27.1% (p = 0.04). In parallel a shift
toward more malignant and more advanced tumour
stages was observed (grading (p = 0.003), T-stage (p =
0.003), N-stage (p < 0.0001) and - consecutively - UICC
stages III and IV (p < .0001) (Table 2). The use of con-
comitant radio-chemotherapy protocols increased con-
tinuously over all time periods, from 37.8% in period I
to a proportion of 86.1% in period V (p < .0001) with a
two agent approach being used most frequently.
Definitive treatment setting increased from 65.7% in per-
iod I to 71% and 78.8% in period III and V respectively.
The application of a definitive RCT increased extremely
after 1993 with a significant difference comparing time
before and after 1998 (p < .0001). A slight decrease in R
(C)T combined with surgery can be observed (n.s.).
Higher radiation doses (54 to 60 Gy) were applied sig-
nificantly more often after 1998.
In order to further validate the results, our own data
were compared with the complete data set documented in
the MCR. In general, MCR covers the region of central
Bavaria, however, these data do not contain detailed radia-
tion data and are restricted to a key set of base line data
including histology, stage, general treatment approach and
outcome. Thus only parts of the results can be validated
using the MRC data. Nevertheless, in the analysis of their
own data the MRC reveals a similar gender-, age- and
tumour stage- distribution over the time (Table 3).
The shift in treatment strategies in the catchment area
of the MRC strongly resembles the in house situation:
Decreasing rates of surgery, radiotherapy only, decreas-
ing rates of surgery and adjuvant radiotherapy only,
increasing use of RCT and RCT+surgery.
Overall survival and prognosis
F i g u r e1s h o w st h eO Sc u r v e sf o rt h ef i v ep e r i o d s .I n
general, no statistically significant improvement in OS
rate was seen over the time course (Figure 2). Even
comparing period I and V, no significant outcome
improvement was observed (Figure 3).
A significant improvement of the OS rates was found
when outcomes after RCT were compared to those after
RT only (p = 0.002), regardless of the chemotherapy
protocol used (2 substances vs. single-agent (n. s.)). In
parallel, a radiation dose higher than 54 Gy seems to
have an influence on survival (p = 0.027), decreasing at
doses higher than 60 Gy (p = 0.04) but only RCT
remains significant in the multivariate Cox proportional
hazard analysis (Table 4)
Yet it is highly noteworthy that the superiority in OS for
patients in the surgery group seen before 1998 (period I-
III) is no longer visible comparing R(C)T versus R(C)T
+surgery for patients diagnosed between 1998 and 2007
(period IV+V) and the OS curves converge (Figures 4a, b).
When patients received R(C)T an improvement (n.s.) in
OS can be observed comparing the periods. There was no
improvement when R(C)T+surgery was performed.
Discussion
Primary aim of this study was to assess changes in basic
clinical characteristics, treatment approaches and their
impact on survival in a very large cohort of patients fol-
lowed over a long period of time. Secondly, we analysed
patterns of change in the use of radio-(chemo)therapy
with or without surgery. For comparison with epidemio-
logical data we included M1 patients but removed them
for not compromising the informative value.
In general, there was a clear shift over the observation
period regarding fundamental patient characteristics
towards higher ages, a higher proportion of adenocarci-
noma and towards more advanced tumour stages at diag-
nosis. Similar tendencies were also visible when analysing
the complete epidemiologic data of the Munich Cancer
Registry. Stage shift and stage migration is - at least in
part - related to an increasing utilisation of improved sta-
ging possibilities including Endo-US, MRI and PET-CT
[16-20].
The increased rate of adenocarcinoma was already
reported by multiple groups world-wide and potentially
reflects a completely different pathogenesis [21-27].
However, the shift towards adenocarcinoma is slightly
less pronounced when compared to the SEER database
(59.2%, n = 16,162; 2004-2008). As opposed to literature
[4,28] we detected a worse OS for AC patients than in
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patient selection in our cohort. The proportion of syn-
chronous malignancies of 11.9% in our cohort is well in
line with published data [29,30].
In general, the prognosis of oesophageal cancer is
dominated by two competing risks: loco-regional relapse
and distant metastases. Surgery as well as radiation as
single modality approaches yield 5 y survival rates below
10% [31]. With both approaches local control rates are
far from being optimal. For this reason surgery, radio-
therapy and chemotherapy were combined in a multi-
modality approach. As expected, in our cohort therapy
options shifted towards multimodality. However, only the
combination of radiotherapy with chemotherapy seems
to impact on overall survival. This has already been
shown in the framework of prospective randomized trials
[8,32,33] and also for patients treated along the given
trial protocols but formally outside of the randomized
trial [7]. However, no such data have been shown for a
non-selected patient cohort. Of special notice in this
regard is the fact that most patients in the Munich set-
ting have received mitomycin-C [13] instead of cisplatin
which was used in most of the randomized trials
[7,8,14,33]. Interestingly, the addition of chemotherapy
only increases local control and was never found to
reduce the high rate of loco-regional and distant seeding.
However, for the whole study cohort the improve-
ments in the field of radio-chemotherapy were not
Table 3 Timetrends, all patients distributed in the five equal time periods (5 y each) and compared to available MCR
data
Time period I: 1983-1987 II: 1988-1992 III: 1993-1997 IV: 1998-2002 V: 2003-2007
n = 143(%) n = 98(%) n = 69(%) n = 108(%) n = 85(%)
Gender M 115(80.4) 76(77.6) 52(75.4) 92(85.2) 65(76.5)
MCR (84.0) (83.2) (83.0) (79.0) (80.4)
Age median y 59 60 59 60 65
MCR 58 59 61 65 66
Histology AC/SCC 23(16.1)/117(81.8) 14(14.3)/81(82.7) 12(17.4)/56(81.2) 23(21.3)/81(75) 23(27.1)/60(70.6)
MCR (16.5)/(83.5) (22.9)/(77.1) (27.6)/(72.4)
Grading G3+4 61(42.7) 48(49) 40(58) 64(59.3) 49(57.6)
T T3+4 76(53.2) 61(62.2) 55(79.7) 90(83.4) 65(76.6)
N1 53(37.1) 36(36.7) 40(58) 65(60.2) 59(69.4)
M1 27(20.9) 17(19.1) 15(22.1) 29(27.6) 25(29.8)
UICC I-IIB 68(47.6) 45(45.9) 24(34.8) 32(29.6) 21(24.7)
MCR (34.4) (37.0) 1988-2007
III-IV 61(42.7) 43(43.9) 43(62.3) 74(68.5) 63(74.1)
MCR (51.1) (63.1) 1988-2007
unknown 14(9.8) 10(10.2) 2(2.9) 2(1.9) 1(1.2)
Therapy definitive 94(65.7) 66(67.3) 49(71) 77(71.3) 67(78.8)
RT/RCT 55(58.5)/38(40.4) 37(56.1)/29(43.9) 13(26.5)/36(73.5) 10(13)/67(87) 11(16.4)/56(83.6)
adjuvant 21(14.7) 4(4.1) 9(13.0) 10(9.3) 7(8.2)
RT/RCT 14(66.7)/4(19) 1(25)/3(75) 3(33.3)/6(66.7) 2(20)/8(80) 0/7(100)
neoadjuvant 20(14.0) 24(24.5) 10(14.5) 19(17.6) 10(11.8)
RT/RCT 7(35)/12(60) 4(16.7)/19(79.2) 2(20)/8(80) 3(15.8)/16(84.2) 1(10)/8(80)
RT, M0-patients 56(56.6) 26(36.1) 13(24.5) 9(11.8) 6(10.3)
RCT, M0-patients 43(43.4) 46(63.9) 40(75.5) 67(88.2) 52(89.7)
Surgery, M0-patients 33(32.7) 22(30.6) 16(30.2) 25(33.8) 16(27.1)
RT dose in Gy, M0-pat. ≤54 45(47.4) 36(50) 23(43.4) 38(51.4) 20(33.9)
> 54 - < 60 4(4.2) 0 6(11.3) 17(23) 27(45.8)
60+ 46(48.4) 36(50) 24(45.3) 19(25.7) 12(20.3)
2D/3D-planning 142(99.3)/0 98(100)/0 65(94.2)/1(1.4) 7(6.5)/99(91.7) 2(2.4)/82(96.5)
Peri-therapy death 19(13.3) 11(11.2) 9(13.0) 15(13.9) 8(9.5)
Therapy break up due to complications 13(9.1) 4(4.1) 7(10.1) 13(12.0) 6(7.1)
Overall survival all/M0 median 18.9/20.7 20.6/26.1 22.6/27.3 20.7/24.3 20.3/29.7
1 y (41.1)/(43.7) (40.2)/(52.2) (44.9)/(54.7) (40.7)/(44.7) (48.8)/(58.7)
3 y (7.1)/(8.7) (15.1)/(18.3) (14.5)/(18.9) (17.6)/(19.7) (15.9)/(19.4)
5 y (4.0)/(5.5) (8.6)/(8.2) (10.1)/(13.2) (9.3)/(11.8) (9.8)/(15.1)
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Thus, despite considerable changes in the treatment
regimens over the past decades results are still moderate
and only a slight improvement in OS was seen in this
unselected patient-cohort.
When trying to determine the role of surgery using
our patient cohort some limitations have to be
considered: The most striking bias is the fact that all
patients have been selected to receive radiotherapy
based on clinical reasons. Thus, the value of surgery can
only be estimated for those patients. In our cohort, the
value of surgery for overall survival seems to be limited.
This is in accordance with the results of randomized
trial showing that the addition of surgery to combined
radio-chemotherapy does not increase OS [3,4,9].
Despite the fact that the best results regarding survival
are achieved in patients with triple modality approaches
the impact on a larger cohort is limited. This is related
to the fact that the increase in mortality by the addition
of surgery counteracts the effects of an increased local
c o n t r o l .T h u s ,n oc l e a rc o n t r i b u t i o no fs u r g e r yt ot h e
outcome is visible in our cohort.
Importantly, radiation dose was related to OS-rates in
this large cohort. In a previous randomized trial [34] no
such correlation was documented. However the value of
this trial is strongly limited since most of the excess
mortality in the higher dose arm occurred early in the
treatment course and several protocol violations were
documented. Our findings are in accordance with data
published by Geh [35] who has provided evidence for
clear dose response relationships for oesophageal cancer
based on dose response data compiled from multiple
trials.
As already pointed out, the use of a non-selected
patient cohort for study purposes is associated with cer-
tain shortcomings: It is impossible to control for imbal-
ances due to individual and location specific clinical
Figure 1 Kaplan-Meier curve for overall survival (OS) for all
M0-patients (n = 362) distributed to the five time-periods.
Figure 2 Kaplan-Meier curve for overall survival (OS) for all
M0-patients (n = 362), comparison between OS for patients
diagnosed between 1983 and 1997 and between 1998 and
2007.
Figure 3 Kaplan-Meier curve for OS for patients diagnosed in
period I (1983-1987) compared to period V (2003-2007),
improvement in OS is not significant (p = 0.08).
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general scientific progress but also by centre specific
variables. Thus, all interpretations need to be very care-
ful, considering selection bias in this retrospective set-
ting for such a long period of time. The patient
characteristics in our unselected cohort are comparable
with whole epidemiologic data set of the Munich Cancer
Registry (MCR) and published trials. Thus the resulting
conclusions are substantiated to some degree. Up to
now only very few other trials have tried to approach
the value of treatment approaches in oesophageal cancer
using population-based data. In this regard a US group
supported by the National Institutes of Health used the
instrument of a survey to collect demographic data on
patient and information on surgical approach for oeso-
phageal carcinoma across the whole country [36]. The
evaluation showed that there is a substantial heterogene-
ity in surgery strategies and emphasized the need of
controlled trials to determine best practices. Another
study from the US queried the SEER database to prove
the benefit of neoadjuvant RT on survival for patients
undergoing definitive surgery [37]. Also by SEER-query
Chang et al. [28] found no difference in survival and
response between AC and SCC across any of the major
treatment modalities.
An investigation on trends in treatment and factors
influencing treatment receipt and survival were sourced
from the Irish National Cancer Registry [38] and
showed decreased use of surgery, especially in older
patients and a considerable difference between the survi-
val observed at population level and in randomised con-
trolled trials.
The MCR and the SEER registry are population-based
databases that represent an unselected group of patients
without consistently recorded medical or course infor-
mation. Therefore only statements concerning epide-
miology and outcomes in actual clinical practice outside
of the controlled setting of research protocols can be
obtained. Although course and recurrence information
is poor in our data and also in the databases, overall
survival is a good surrogate for disease recurrence,
because the outcomes with oesophageal cancer are poor
Table 4 Cox Regression Analysis, HR = Hazard Ratio calculated with 95% confidence interval (CI) by Cox-proportional
hazard model
Overall survival
Univariate p, HR(95%CI) Multivariate p, HR(95%CI)
Comparison
Therapy prim vs adj+neoadj RCT 0.096, 1.23 (0.97-1.56)
RCT vs RT 0.002, 0.69(0.54-0.87) 0.02, 0.74(0.58-0.98)
1 agent vs 2 agents 0.34, 1,04(0.97-1.11)
RT dose in Gy ≥54 Gy vs < 54 Gy 0.027, 0.78(0.62-0.97) 0.18, 0.85(0.67-1.089
2D/3Dplanning 2D vs 3D 0.71, 0.98(0.76-1.2)
Figures 4 Kaplan-Meier curves for OS for patients diagnosed
between 1983 and 1997 who received R(C)T compared to R(C)
T+surgery presenting a better outcome (4a) and presenting no
difference in OS in the two therapy groups between 1998 and
2007 (4b).
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Cause of death and mortality data are available and gen-
erally corresponds to disease recurrence.
Despite the fact that the results of several large rando-
mized trials are available the general progress in oeso-
phageal cancer is limited. In the future, several crucial
aspects are of importance: A key problem is the fact
that a considerable number of patients are not suitable
for aggressive approaches [39]. Hence, major efforts
should be placed on the development of tools for accu-
rate patient selection according to the individual risk
situation and estimated prognosis and reducing therapy
associated morbidity and mortality [22,25,31,40,41]. In
this regard, important contributions may come from
similar disorders including head and neck cancer or
lung cancer in which the development of modern ima-
ging approaches as well as biological stratification
approaches already dominate the research horizon
[42,43].
In parallel, the fate of patients with oesophageal can-
cer is largely influenced by early dissemination, thus it is
of key importance to test the value of an integration of
targeted drugs with proven activity in either SCC or AC
into putative new treatment protocols [44-46]. Similarly,
new radiation techniques suitable to reduce lung toxicity
or increase target volume conformity [47-50] will have a
clear role in optimizing the outcomes in oesophageal
cancer.
Conclusion
D e s p i t ea ni n c r e a s ei nu n f a v o u r a b l et u m o u rs t a g e sa
slight (but statistically insignificant) improvement of sur-
vival for the whole cohort can be observed, which can
be mainly attributed to the addition of chemotherapy to
radiotherapy. The role of surgery for most of the
patients with locally advanced disease is not fully deter-
mined. Despite all efforts in the field of multimodal
approaches, prognosis of oesophageal cancer is still
limited.
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